Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

599 results
Display

Microbiome and metabolomics in alcoholic liver disease

Ganesan R, Suk KT

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Lee HA, Chang Y, Sung PS, Yoon EL, Lee HW, Yoo JJ, Lee YS, An J, Song DS, Cho YY, Kim SU, Kim YJ

The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological treatment...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Jin Q, Yang RX, Fan JG

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Hwang S, Kim W

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, Tan DJH, Khoo CM, Goh LH, Ling ZJ, Kulkarni A, Mak LYL, Huang DQ, Chan M, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M

Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is closely associated with diabetes. The cumulative impact of both diseases synergistically increases risk of adverse events. However, present population analysis is predominantly conducted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults

Ye BS

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients

Cheung KS, Lam LK, Hui RWH, Mao X, Zhang RR, Chan KH, Hung IF, Seto WK, Yuen MF

Background/Aims: Studies of hepatic steatosis (HS) effect on COVID-19 vaccine immunogenicity are lacking. We aimed to compare immunogenicity of BNT162b2 and CoronaVac among moderate/severe HS and control subjects. Methods: Two hundred...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study

Kim JH, Jun BG, Lee M, Lee HA, Kim TS, Heo JW, Moon DH, Kang SH, Suk KT, Kim MY, Kim YD, Cheon GJ, Baik SK, Kim DJ, Choi DH

Background/Aims: Sepsis-3 criteria and quick Sequential Organ Failure Assessment (qSOFA) have been advocated to be used in defining sepsis in the general population. We aimed to compare the Sepsis-3 criteria...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4

Liu Y, Zhang X, Chen S, Wang J, Yu S, Li Y, Xu M, Aboubacar H, Li J, Shan T, Wang J, Cao G

Background/Aims: Binge drinking leads to many disorders, including alcoholic hepatosteatosis, which is characterized by intrahepatic neutrophil infiltration and increases the risk of hepatocellular carcinoma (HCC). Molecular mechanisms may involve the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial

Oh JH, Jun DW, Kim HY, Lee SM, Yoon EL, Hwang J, Park JH, Lee H, Kim W, Kim H

Background/Aims: We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD). Methods: An exploration study (study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Iwamoto H, Shimose S, Niizeki T, Koga H, Torimura T, The Kurume Liver Cancer Study Group of Japan

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults

Jeong S, Oh YH, Choi S, Chang J, Kim SM, Son JS, Lee G, Ahn JC, Lee DH, Koo BK, Kim W, Park SM

Background/Aims: Accumulating evidence suggests a link between non-alcoholic fatty liver disease (NAFLD) and brain health. However, population-based evidence on the association between NAFLD and dementia remains unclear. This study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals

Tang ASP, Chan KE, Quek J, Xiao J, Tay P, Teng M, Lee KS, Lin SY, Myint MZ, Tan B, Sharma VK, Tan DJH, Lim WH, Kaewdech A, Huang D, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M, Ng CH

Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is associated with the development of cardiovascular disease. While existing studies have examined cardiac remodeling in NAFLD, there has been less emphasis on the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
RNA interference as a novel treatment strategy for chronic hepatitis B infection

Hui RWH, Mak LY, Seto WK, Yuen MF

Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance

Komuta M

Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?

Goh MJ, Sinn DH

Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound

Park J, Lee JM, Kim TH, Yoon JH

Hepatocellular carcinoma (HCC) is a unique cancer entity that can be noninvasively diagnosed using imaging modalities without pathologic confirmation. In 2018, several major guidelines for HCC were updated to include...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Yu JH, Cho SG, Jin YJ, Lee JW

Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

Sung PS

The tumor microenvironment generally shows a substantial immunosuppressive activity in hepatocellular carcinoma (HCC), accounting for the suboptimal efficacy of immune-based treatments for this difficult-to-treat cancer. The crosstalk between tumor cells...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KASL clinical practice guidelines for management of chronic hepatitis B

The Korean Association for the Study of the Liver (KASL)

CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr